Keybanc Maintains Overweight on NeuroPace, Lowers Price Target to $14
Keybanc analyst Brett Fishbin maintains NeuroPace (NASDAQ:NPCE) with a Overweight and lowers the price target from $18 to $14.
Last updated: 2026-11-14 02:02:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Neuropace, Inc. (NPCE) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $7.67, with a market capitalization of $412.58M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.48 to $19.60. This page covers its latest market performance, valuation, price trends and company information.
$412.58M | |
$6.25 | |
$8.33 | |
$5.48 | |
$12.02 | |
5.90M | |
125.73K | |
-- | |
$19.60 | |
$5.48 | |
-- | |
-- |
Neuropace, Inc. (NPCE) last closed at $7.67 as of 2026-11-14 01:00:00, down 35.90% ($4.31) from the previous close of $12.02.
During the latest regular trading session, NPCE traded between $5.48 and $8.33, with a volume of 5.90M shares. The closing price was near the upper end and near the lower end of its 52-week range.
NPCE is down 0.35% as of the last close.
Over the past seven days, Neuropace, Inc. (NPCE) moved from $12.69 to $7.67, representing a decline of 39.60% ($5.02).
The stock traded between $5.48 and $13.48 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 123.87 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 15.5%
NPCE is currently trading at $7.67, placing it 15.5% of the way from its 52-week low of $5.48 to its 52-week high of $19.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 220 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Neuropace, Inc. and NPCE stock.
Keybanc analyst Brett Fishbin maintains NeuroPace (NASDAQ:NPCE) with a Overweight and lowers the price target from $18 to $14.
Leerink Partners analyst Mike Kratky downgrades NeuroPace (NASDAQ:NPCE) from Outperform to Market Perform and announces $7 price target.
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report
NeuroPace shares tumble after-hours after missing revenue estimates and cutting 2026 sales guidance.
NeuroPace (NPCE) reported a quarterly loss of $0.03 per share, beating consensus estimates of $0.06 loss by 50%, but missed revenue expectations with $23.1 million versus the estimated $26.9 million. The company has underperformed the S&P 500 by 30.2% year-to-date. With mixed estimate revisions, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Eligible investors can buy real shares of Neuropace, Inc. (NPCE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NPCE, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between NPCE shares and USD.
NPCE Shares to USD
1.00 NPCE shares = 7.665 USD
Calculations are estimates based on the latest available price and are for reference only.